Details
| Stereochemistry | EPIMERIC |
| Molecular Formula | C39H48N4O4 |
| Molecular Weight | 636.8228 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 2 / 3 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CCCCCCOC(C)C1=C(C)C2=CC3=NC([C@@H](CCC(O)=O)[C@@H]3C)=C4CC(=O)C5=C4NC(C=C6N=C(C=C1N2)C(C)=C6CC)=C5C
InChI
InChIKey=PVXGCBZIVFCMJK-NMWXTPPCSA-N
InChI=1S/C39H48N4O4/c1-8-10-11-12-15-47-24(7)36-22(5)30-17-29-21(4)26(13-14-35(45)46)38(42-29)27-16-34(44)37-23(6)31(43-39(27)37)18-32-25(9-2)20(3)28(40-32)19-33(36)41-30/h17-19,21,24,26,41,43H,8-16H2,1-7H3,(H,45,46)/b28-19-,29-17-,30-17-,31-18-,32-18-,33-19-,38-27-/t21-,24?,26-/m0/s1
2-(1-Hexyloxyethyl)-2-devinyl pyropheophorbide-a (HPPH), a chlorin-based photosensitize, is used in photodynamic therapy. It has been shown the therapeutic potential of HPPH in phase II clinical trials for the treatment of esophageal cancer. Besides, HPPH participated in clinical trials in treating patients with advanced non-small cell lung cancer that blocks the air passages. However, these studies were terminated.
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Suppression of LPS-induced matrix-metalloproteinase responses in macrophages exposed to phenytoin and its metabolite, 5-(p-hydroxyphenyl-), 5-phenylhydantoin. | 2010-09-15 |
|
| Determination of phenytoin and its major metabolite in human serum by MEKC. | 2009-11-26 |
|
| CYP2C9 amino acid residues influencing phenytoin turnover and metabolite regio- and stereochemistry. | 2009-06 |
|
| Phenytoin metabolite renal calculus: an index case. | 2008-08 |
|
| High-performance liquid chromatographic method for determination of phenytoin in rabbits receiving sildenafil. | 2008-04-18 |
|
| Stereoselective glucuronidation of 5-(4'-hydroxyphenyl)-5-phenylhydantoin by human UDP-glucuronosyltransferase (UGT) 1A1, UGT1A9, and UGT2B15: effects of UGT-UGT interactions. | 2007-09 |
|
| Paradoxical urinary phenytoin metabolite (S)/(R) ratios in CYP2C19*1/*2 patients. | 2006-09 |
|
| Studies by biointeraction chromatography of binding by phenytoin metabolites to human serum albumin. | 2006-05-19 |
|
| Influence of the CYP2C9 AND CYP2C19 polymorphisms on phenytoin hydroxylation in healthy individuals from south India. | 2006-05 |
|
| CYP2C9, CYP2C19, ABCB1 (MDR1) genetic polymorphisms and phenytoin metabolism in a Black Beninese population. | 2005-11 |
|
| Analytic performance evaluation of a new turbidimetric immunoassay for phenytoin on the ADVIA 1650 analyzer: effect of phenytoin metabolite and analogue. | 2005-06 |
|
| Urinary excretion of phenytoin metabolites, 5-(4'-hydroxyphenyl)-5-phenylhydantoin and its O-glucuronide in humans and analysis of genetic polymorphisms of UDP-glucuronosyltransferases. | 2005-04 |
|
| The effects of phenytoin and its metabolite 5-(4-hydroxyphenyl)-5-phenylhydantoin on cellular glucose transport. | 2005-03-04 |
|
| Key structural features of ligands for activation of human pregnane X receptor. | 2004-04 |
|
| Involvement of multiple UDP-glucuronosyltransferase 1A isoforms in glucuronidation of 5-(4'-hydroxyphenyl)-5-phenylhydantoin in human liver microsomes. | 2002-11 |
|
| Effects of cysteine on the pharmacokinetics of intravenous phenytoin in rats with protein-calorie malnutrition. | 2001-10-23 |
|
| Phenytoin metabolic ratio: a putative marker of CYP2C9 activity in vivo. | 2001-10 |
|
| Effect of mild therapeutic hypothermia on phenytoin pharmacokinetics. | 2001-06 |
|
| Stereoselective determination of p-hydroxyphenyl-phenylhydantoin enantiomers in rat liver microsomal incubates by reversed-phase high-performance liquid chromatography using beta-cyclodextrin as chiral mobile phase additives. | 2001-04 |
|
| Inhibition of phenytoin hydroxylation in human liver microsomes by several selective serotonin re-uptake inhibitors. | 2001-04 |
|
| Stable expression of a human liver UDP-glucuronosyltransferase (UGT2B15) with activity toward steroid and xenobiotic substrates. | 1994-09-01 |
Patents
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
FDA ORPHAN DRUG |
640418
Created by
admin on Mon Mar 31 18:13:09 GMT 2025 , Edited by admin on Mon Mar 31 18:13:09 GMT 2025
|
||
|
NCI_THESAURUS |
C1420
Created by
admin on Mon Mar 31 18:13:09 GMT 2025 , Edited by admin on Mon Mar 31 18:13:09 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
149402-51-7
Created by
admin on Mon Mar 31 18:13:09 GMT 2025 , Edited by admin on Mon Mar 31 18:13:09 GMT 2025
|
PRIMARY | |||
|
DTXSID501028872
Created by
admin on Mon Mar 31 18:13:09 GMT 2025 , Edited by admin on Mon Mar 31 18:13:09 GMT 2025
|
PRIMARY | |||
|
DOB7Y3RSX0
Created by
admin on Mon Mar 31 18:13:09 GMT 2025 , Edited by admin on Mon Mar 31 18:13:09 GMT 2025
|
PRIMARY | |||
|
DB15243
Created by
admin on Mon Mar 31 18:13:09 GMT 2025 , Edited by admin on Mon Mar 31 18:13:09 GMT 2025
|
PRIMARY | |||
|
2-(1-Hexyloxyethyl)-2-devinyl pyropheophorbide-a
Created by
admin on Mon Mar 31 18:13:09 GMT 2025 , Edited by admin on Mon Mar 31 18:13:09 GMT 2025
|
PRIMARY | |||
|
C2636
Created by
admin on Mon Mar 31 18:13:09 GMT 2025 , Edited by admin on Mon Mar 31 18:13:09 GMT 2025
|
PRIMARY |
SUBSTANCE RECORD
